Mechanism of action for respiratory syncytial virus inhibitor RSV604

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 2, 2015, Pages 1080-1087

  Challa, SreeRupa ^a   Scott, Andrew D ^a   Yuzhakov, Olga ^a   Zhou, Ying ^a   Tiong Yip, Choi Lai ^a   Gao, Ning ^a   Thresher, Jason ^a   Yua, Qin ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (2 FLUOROPHENYL)UREA; DIMETHYL SULFOXIDE; GUANINE NUCLEOTIDE BINDING PROTEIN; VIRUS PROTEIN; VIRUS RNA; 1-(2-FLUOROPHENYL)-3-(2-OXO-5-PHENYL-2,3-DIHYDRO-1H-BENZO(E)(1,4)DIAZEPIN-3-YL)UREA; BENZODIAZEPINE DERIVATIVE; CARBANILAMIDE DERIVATIVE;

ARTICLE; BINDING AFFINITY; CELL INCLUSION; CELL SURFACE; CONFOCAL LASER MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY ASSAY; DRUG PROTEIN BINDING; ENZYME LINKED IMMUNOSORBENT ASSAY; HELA CELL LINE; HUMAN; HUMAN CELL; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOFLUORESCENCE; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REPLICON CELL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SYNTHESIS; SURFACE PLASMON RESONANCE; VIRUS INFECTIVITY; VIRUS REPLICATION; CELL LINE; DRUG EFFECTS;

BENZODIAZEPINONES; CELL LINE; HUMANS; PHENYLUREA COMPOUNDS; RESPIRATORY SYNCYTIAL VIRUSES; RNA, VIRAL; VIRUS REPLICATION;

EID: 84921904004     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04119-14     Document Type: Article

References (30)

1. Borchers AT, Chang C, Gershwin ME, Gershwin LJ. 2013. Respiratory syncytial virus-a comprehensive review. Clin Rev Allergy Immunol 45: 331-379. http://dx.doi.org/10.1007/s12016-013-8368-9.
2. Nair H, Simoes EA, Rudan I, Gessner BD, Azziz-Baumgartner E, Zhang JS, Feikin DR, Mackenzie GA, Moisi JC, Roca A, Baggett HC, Zaman SM, Singleton RJ, Lucero MG, Chandran A, Gentile A, Cohen C, Krishnan A, Bhutta ZA, Arguedas A, Clara AW, Andrade AL, Ope M, Ruvinsky RO, Hortal M, McCracken JP, Madhi SA, Bruce N, Qazi SA, Morris SS, El Arifeen S, Weber MW, Scott JA, Brooks WA, Breiman RF, Campbell H, Severe Acute Lower Respiratory Infections Working Group. 2013. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010: a systematic analysis. Lancet 381:1380-1390. http://dx.doi.org/10.1016/S0140 -6736(12)61901-1.
3. Collins PL, Fearns R, Graham BS. 2013. Respiratory syncytial virus: virology, reverse genetics, and pathogenesis of disease. Curr Top Microbiol Immunol 372:3-38. http://dx.doi.org/10.1007/978-3-642 -38919-1-1.
4. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults.NEngl J Med 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
5. Roymans D, Koul A. 2011. Treatment of respiratory syncytial virus infection: past, present and future. In Resch B (ed), Human Respiratory Syncytial Virus Infection. InTech.
6. DeVincenzo J, Lambkin-Williams R, Wilkinson T, Cehelsky J, Nochur S, Walsh E, Meyers R, Gollob J, Vaishnaw A. 2010. A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A 107: 8800-8805. http://dx.doi.org/10.1073/pnas.0912186107.
7. Zamora MR, Budev M, Rolfe M, Gottlieb J, Humar A, Devincenzo J, Vaishnaw A, Cehelsky J, Albert G, Nochur S, Gollob JA, Glanville AR. 2011. RNA interference therapy in lung transplant patients infected with respiratory syncytial virus. Am J Respir Crit Care Med 183:531-538. http: //dx.doi.org/10.1164/rccm.201003-0422OC.
8. Debing Y, Jochmans D, Neyts J. 2013. Intervention strategies for emerging viruses: use of antivirals. Curr Opin Virol 3:217-224. http://dx.doi.org /10.1016/j.coviro.2013.03.001.
9. Chapman J, Abbott E, Alber DG, Baxter RC, Bithell SK, Henderson EA, Carter MC, Chambers P, Chubb A, Cockerill GS, Collins PL, Dowdell VC, Keegan SJ, Kelsey RD, Lockyer MJ, Luongo C, Najarro P, Pickles RJ, Simmonds M, Taylor D, Tyms S, Wilson LJ, Powell KL. 2007. RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother 51: 3346-3353. http://dx.doi .org/10.1128/AAC.00211-07.
10. Roymans D, Koul A. 2010. Respiratory syncytial virus: a prioritized or neglected target? Future Med Chem 2:1523-1527. http://dx.doi.org/10 .4155/fmc.10.235.
11. DeVincenzo JP, Whitley RJ, Mackman RL, Scaglioni-Weinlich C, Harrison L, Farrell E, McBride S, Lambkin-Williams R, Jordan R, Xin Y, Ramanathan S, O'Riordan T, Lewis SA, Li X, Toback SL, Lin SL, Chien JW. 2014. Oral GS-5806 activity in a respiratory syncytial virus challenge study. New Engl J Med 371: 711-722. http://dx.doi.org /10.1056/NEJMoa1401184.
12. Marty FM, Chemaly RF, Liakopoulou E, Dent JC, PK. 2007. A doubleblind, randomised, placebo-controlled study to evaluate the safety and efficacy of RSV604 in adults with respiratory syncytial virus (RSV) infection following stem cell transplantation. IX International Symposium on Respiratory Viral Infections, Hong Kong, China.
13. Henderson EA, Alber DG, Baxter RC, Bithell SK, Budworth J, Carter MC, Chubb A, Cockerill GS, Dowdell VC, Fraser IJ, Harris RA, Keegan SJ, Kelsey RD, Lumley JA, Stables JN, Weerasekera N, Wilson LJ, Powell KL. 2007. 1,4-Benzodiazepines as inhibitors of respiratory syncytial virus. The identification of a clinical candidate. J Med Chem 50:1685-1692. http://dx.doi.org/10.1021/jm060747l.
14. Kao RY, Yang D, Lau LS, Tsui WH, Hu L, Dai J, Chan MP, Chan CM, Wang P, Zheng BJ, Sun J, Huang JD, Madar J, Chen G, Chen H, Guan Y, Yuen KY. 2010. Identification of influenza A nucleoprotein as an antiviral target. Nat Biotechnol 28:600-605. http://dx.doi.org/10.1038 /nbt.1638.
15. Amorim MJ, Kao RY, Digard P. 2013. Nucleozin targets cytoplasmic trafficking of viral ribonucleoprotein-Rab11 complexes in influenza A virus infection. J Virol 87:4694 - 4703. http://dx.doi.org/10.1128/JVI .03123-12.
16. Cianci C, Gerritz SW, Deminie C, Krystal M. 2013. Influenza nucleoprotein: promising target for antiviral chemotherapy. Antivir Chem Chemother 23:77-91. http://dx.doi.org/10.3851/IMP2235.
17. Malykhina O, Yednak MA, Collins PL, Olivo PD, Peeples ME. 2011. A respiratory syncytial virus replicon that is noncytotoxic and capable of long-term foreign gene expression. J Virol 85:4792-4801. http://dx.doi .org/10.1128/JVI.02399-10.
18. Tiong-Yip CL, Aschenbrenner L, Johnson KD, McLaughlin RE, Fan J, Challa S, Xiong H, Yu Q. 2014. Characterization of a respiratory syncytial virus L protein inhibitor. Antimicrob Agents Chemother 58:3867-3873. http://dx.doi.org/10.1128/AAC.02540-14.
19. Graham BS, Perkins MD, Wright PF, Karzon DT. 1988. Primary respiratory syncytial virus infection in mice. J Med Virol 26:153-162. http://dx .doi.org/10.1002/jmv.1890260207.
20. Tiong-Yip CL, Plant H, Sharpe P, Fan J, Rich K, Gorseth E, Yu Q. 2014. Development of a high-throughput replicon assay for the identification of respiratory syncytial virus inhibitors. Antiviral Res 101:75-81. http://dx .doi.org/10.1016/j.antiviral.2013.11.003.
21. Bannister R, Rodrigues D, Murray EJ, Laxton C, Westby M, Bright H. 2010. Use of a highly sensitive strand-specific quantitative PCR to identify abortive replication in the mouse model of respiratory syncytial virus disease. Virol J 7:250. http://dx.doi.org/10.1186/1743-422X-7-250.
22. Mason SW, Lawetz C, Gaudette Y, Do F, Scouten E, Lagace L, Simoneau B, Liuzzi M. 2004. Polyadenylation-dependent screening assay for respiratory syncytial virus RNA transcriptase activity and identification of an inhibitor. Nucleic Acids Res 32:4758-4767. http://dx.doi.org/10.1093 /nar/gkh809.
23. Li D, Jans DA, Bardin PG, Meanger J, Mills J, Ghildyal R. 2008. Association of respiratory syncytial virusMprotein with viral nucleocapsids is mediated by the M2-1 protein. J Virol 82:8863-8870. http://dx.doi .org/10.1128/JVI.00343-08.
24. Magliano D, Marshall JA, Bowden DS, Vardaxis N, Meanger J, Lee JY. 1998. Rubella virus replication complexes are virus-modified lysosomes. Virology 240:57-63. http://dx.doi.org/10.1006/viro.1997.8906.
25. Shapiro AB, Gao N, O'Connell N, Hu J, Thresher J, Gu RF, Overman R, Hardern IM, Sproat GG. 2014. Quantitative investigation of the affinity of human respiratory syncytial virus phosphoprotein C-terminus binding to nucleocapsid protein. Virol J 11:191. http://dx.doi.org/10.1186 /s12985-014-0191-2.
26. El Omari K, Scott K, Dhaliwal B, Ren J, Abrescia NG, Budworth J, Lockyer M, Powell KL, Hawkins AR, Stammers DK. 2008. Crystallization and preliminary X-ray analysis of the human respiratory syncytial virus nucleocapsid protein. Acta Crystallogr Sect F Struct Biol Cryst Commun 64:1019-1023. http://dx.doi.org/10.1107/S1744309108031059.
27. Hacking D, Hull J. 2002. Respiratory syncytial virus-viral biology and the host response. J Infect 45:18-24. http://dx.doi.org/10.1053/jinf.2002 .1015.
28. Tawar RG, Duquerroy S, Vonrhein C, Varela PF, Damier-Piolle L, Castagne N, MacLellan K, Bedouelle H, Bricogne G, Bhella D, Eleouet JF, Rey FA. 2009. Crystal structure of a nucleocapsid-like nucleoprotein-RNA complex of respiratory syncytial virus. Science 326:1279-1283. http: //dx.doi.org/10.1126/science.1177634.
29. Carromeu C, Simabuco FM, Tamura RE, Farinha Arcieri LE, Ventura AM. 2007. Intracellular localization of human respiratory syncytial virus L protein. Arch Virol 152:2259-2263. http://dx.doi.org/10.1007/s00705 -007-1048-4.
30. Garcia J, Garcia-Barreno B, Vivo A, Melero JA. 1993. Cytoplasmic inclusions of respiratory syncytial virus-infected cells: formation of inclusion bodies in transfected cells that coexpress the nucleoprotein, the phosphoprotein, and the 22K protein. Virology 195:243-247. http://dx.doi.org /10.1006/viro.1993.1366.